

These figures demonstrate that the Controlled Substances Act has accomplished a dramatic reduction in the prescription of amphetamine anorectic products, but that a continuing medical requirement for those products remains.

The figures also demonstrate that while there has been an overall reduction in the total prescriptions of anorectic products, there also remains a very sizable patient population, consisting of millions of Americans, among the 30 to 40 million obese, who are receiving medically supervised treatment for their condition.

Pennwalt's Manufacture, Distribution and Sales

All of the federal regulations I described previously are complied with by Pennwalt in its manufacture, distribution and sales. In addition, at the plant, production and shipping are monitored closely by management to assure the absence of loss and the detection of any attempted theft. As noted earlier, detailed records and monthly and quarterly reports to the DEA show each transaction both intra-plant and to customers, its size and the identity of the customer.

At the present time, Pennwalt sells its prescription products, including Biphedamine and Ionamin, only to non-profit hospitals and to approximately 450 wholesale distributors.

These wholesalers handle the complete line of Pennwalt products and all of them are also registered and regulated in their handling of scheduled drugs by the Drug Enforcement Administration. In addition to registration, the wholesalers are subject to the same stringent reporting requirements by the DEA as is required of manufacturers.